Polar Capital Holdings Plc Reports 8.46% Stake in Enliven Therapeutics, Inc. (ELVN)

Polar Capital Holdings Plc, along with its affiliates Polar Capital LLP and the Polar Capital Funds PLC - Biotechnology Fund, filed a Schedule 13G/A on May 15, 2026, disclosing a significant stake in Enliven Therapeutics, Inc. (ELVN). According to the filing, the group collectively owns 5,056,807 shares of Common Stock, representing an 8.46% ownership stake in the company. This calculation is based on 60,904,946 shares outstanding as reported in Enliven's Form 10-Q from May 7, 2026. The filing indicates that Polar Capital Holdings Plc and its subsidiaries have sole voting and dispositive power over the entire reported share count. The reporting persons are based in the United Kingdom and Ireland. This amendment confirms that the shares were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer. The event triggering this filing occurred on March 31, 2026.